TABLE 1

Design and sampling of DENV infection studies in cynomolgus macaques

Group (no. of animals)Immunizations and challengesBlood sampling days
Virus (inoculation day[s])Dose (CCID50); route of injection
Study A
    A, B, C (5)DENV-2 (0)5 log10; s.c. (A), i.d. (B), i.v. (C)1–14
    D, E, F (5)DENV-2 (0)7 log10; s.c. (D), i.d. (E), i.v. (F)1–14
Study B
    A, B, C (6)CYD-TDV (0, 56)5 log10/serotype/dose; s.c.1–14, 28, 49, 84, 149, 305
DENV-2 (315)7 log10; i.v.1–14, 28 postchallenge
    D (6), E (7)MV-CYD-2 (0, 56)5 log10/serotype/dose; s.c.1–14, 28, 49, 84, 149, 305
DENV-2 (315)7 log10; i.v.1, 14, 28 postchallenge
    F (7)DENV-2 (315)7 log10; i.v.1–14, 28 postchallenge
Study C
    A, B (6)CYD-TDV (0, 56)5 log10/serotype/dose; s.c.1–14, 28, 49, 84, 149, 305
DENV-2 (315)7 log10; i.v.1–14, 28 postchallenge
    C, D (6)CYD-TDV (0, 56)5 log10/serotype/dose; s.c.1–14, 28, 49, 84, 149, 305
DENV-4 (315)7 log10; i.v.1–14, 28 postchallenge